REG - Destiny Pharma PLC - Notice of Interim Results

Destiny PharmaAnnouncement

23/08/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230823:nRSW1006Ka&default-theme=true

RNS Number : 1006K  Destiny Pharma PLC  23 August 2023

23 August 2023

 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Notice of Interim Results

 

Brighton, United Kingdom - Destiny Pharma (AIM: DEST), a clinical stage
biotechnology company focused on the development and commercialisation of
novel medicines to prevent and treat life threatening infections, will
announce its interim results for the period ended 30 June 2023 on Wednesday 20
September 2023.

 

On 20 September 2023, the Company will host a briefing for analysts at 8.30am
BST, followed by a presentation to all existing and potential shareholders at
11.00am BST held via the Investor Meet Company platform. Further details for
the analyst briefing will be shared by invitation in due course.

 

The analyst briefing and investor presentation will be led by Chris Tovey, the
incoming Chief Executive Officer set to join the Company on Friday 1 September
2023, and Shaun Claydon, Chief Financial Officer.

 

Questions can be submitted pre-event via the Investor Meet Company dashboard
up until 9.00 am BST the day before the meeting, or at any time during the
live presentation.

 

Investors can sign up to Investor Meet Company for free, and add to
meet Destiny Pharma plc via:
https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
(https://url.avanan.click/v2/___https:/www.investormeetcompany.com/destiny-pharma-plc/register-investor___.YXAxZTpzaG9yZWNhcDphOm86MDM0ZWViODVlZWE3NTM5MWYwNjBjYzBmNmFkZDJlNzc6NjpmNjA4OjliZTcxZWIwYWM3ZmQ0NTIwNmE0OWM4NjIzZmE3MDVhODJjNmEyMjFhN2QwYTQ5YTdiMTU5OGQ2NzY1ZDE0MzM6cDpU)

 

Investors who already follow Destiny Pharma plc on the Investor Meet Company
platform will automatically be invited.

 

- END -

For further information, please contact:

 

Destiny Pharma plc
Debra Barker, Interim CEO

Shaun Claydon, CFO

+44 (0)1273 704 440
pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

Powerscourt Group
Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward

+44 (0) 20 7250 1446

Destiny@powerscourt-group.com (mailto:Destiny@powerscourt-group.com)

finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. Its pipeline has novel microbiome-based
biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready
treatment for the prevention of C. difficile infection (CDI) recurrence
which is the leading cause of hospital acquired infection in the US and also
XF-73 nasal gel, which has recently completed a positive Phase 2 clinical
trial targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SPOR-COV(TM), a novel,
biotherapeutic product for the prevention of COVID-19 and other viral
respiratory infections and has earlier grant funded XF drug research projects.

 

For further information on the company, please visit www.destinypharma.com
(https://url.avanan.click/v2/___http:/www.destinypharma.com/___.YXAxZTpzaG9yZWNhcDphOm86MDM0ZWViODVlZWE3NTM5MWYwNjBjYzBmNmFkZDJlNzc6Njo5OGNmOjU0Nzc4YTZjMzRiMWQxM2EyODFkYmFmMzNmMzU1ZjM5ZWY5MmRkNThjMGMwOGZiNjRjMzQ1YmFiY2I0YmU1ODQ6cDpU)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFLFLITLIFFIV